dc.creator | Sargas, C. | es |
dc.creator | Ayala, R. | es |
dc.creator | Larráyoz, M. J. | es |
dc.creator | Chillón, M. C. | es |
dc.creator | Rodríguez-Arboli, E. | es |
dc.creator | Bilbao, C. | es |
dc.creator | Pérez Simón, José Antonio | es |
dc.creator | Montesinos, P. | es |
dc.date.accessioned | 2024-04-26T13:27:45Z | |
dc.date.available | 2024-04-26T13:27:45Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Sargas, C., Ayala, R., Larráyoz, M.J., Chillón, M.C., Rodríguez-Arboli, E., Bilbao, C.,...,Montesinos, P. (2023). Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer Journal, 13 (1), 77. https://doi.org/10.1038/s41408-023-00835-5. | |
dc.identifier.issn | 2044-5385 | es |
dc.identifier.uri | https://hdl.handle.net/11441/157218 | |
dc.description.abstract | Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European
LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively
and 379 non-intensively treated patients. Among fit patients, those aged ≥65 years old showed worse OS than younger regardless
risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification,
increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable
and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a
predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017
intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations.
Patients with one MDS-related mutation did not reach median OS, while patients with ≥2 mutations had 13.6 months median OS
(P = 0.002). Patients with TP53 ± complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the
prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification
guidelines. | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Springer Nature | es |
dc.relation.ispartof | Blood Cancer Journal, 13 (1), 77. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.contributor.affiliation | Instituto de Biomedicina de Sevilla (IBIS) | es |
dc.relation.publisherversion | https://www.nature.com/articles/s41408-023-00835-5 | es |
dc.identifier.doi | 10.1038/s41408-023-00835-5 | es |
dc.journaltitle | Blood Cancer Journal | es |
dc.publication.volumen | 13 | es |
dc.publication.issue | 1 | es |
dc.publication.initialPage | 77 | es |